These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 29335345)
1. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis. Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345 [TBL] [Abstract][Full Text] [Related]
2. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis. Funk RS; Chan MA; Becker ML Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276 [TBL] [Abstract][Full Text] [Related]
3. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Hinze CH; Foell D; Johnson AL; Spalding SJ; Gottlieb BS; Morris PW; Kimura Y; Onel K; Li SC; Grom AA; Taylor J; Brunner HI; Huggins JL; Nocton JJ; Haines KA; Edelheit BS; Shishov M; Jung LK; Williams CB; Tesher MS; Costanzo DM; Zemel LS; Dare JA; Passo MH; Ede KC; Olson JC; Cassidy EA; Griffin TA; Wagner-Weiner L; Weiss JE; Vogler LB; Rouster-Stevens KA; Beukelman T; Cron RQ; Kietz D; Schikler K; Mehta J; Ting TV; Verbsky JW; Eberhard AB; Huang B; Giannini EH; Lovell DJ Arthritis Rheumatol; 2019 Mar; 71(3):451-459. PubMed ID: 30225949 [TBL] [Abstract][Full Text] [Related]
4. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Anink J; Van Suijlekom-Smit LW; Otten MH; Prince FH; van Rossum MA; Dolman KM; Hoppenreijs EP; ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Vogl T; Gohar F; Foell D; Roth J; Holzinger D Arthritis Res Ther; 2015 Aug; 17(1):200. PubMed ID: 26249667 [TBL] [Abstract][Full Text] [Related]
5. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Brunner HI; Schulert GS; Sproles A; Thornton S; Cornejo GV; Antón J; Cuttica R; Henrickson M; Foeldvari I; Kingsbury DJ; Askelson M; Liu J; Mukherjee S; Wong RL; Lovell DJ; Martini A; Ruperto N; Grom AA; Arthritis Res Ther; 2024 Jun; 26(1):125. PubMed ID: 38918871 [TBL] [Abstract][Full Text] [Related]
6. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis. Swart JF; van Dijkhuizen EHP; Wulffraat NM; de Roock S Ann Rheum Dis; 2018 Mar; 77(3):336-342. PubMed ID: 29138257 [TBL] [Abstract][Full Text] [Related]
7. Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor. Yamasaki Y; Takei S; Imanaka H; Nerome Y; Kubota T; Nonaka Y; Akaike H; Takezaki T; Kawano Y Mod Rheumatol; 2016 Jul; 26(4):551-6. PubMed ID: 26474088 [TBL] [Abstract][Full Text] [Related]
8. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry. Foeldvari I; Becker I; Horneff G Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824 [TBL] [Abstract][Full Text] [Related]
9. Role of Serum MRP8/14 in Predicting Response to Methotrexate in Children With Juvenile Idiopathic Arthritis. Bagri NK; Karmakar S; Haldar P; Lodha R; Kabra SK J Clin Rheumatol; 2021 Dec; 27(8):e336-e341. PubMed ID: 32658390 [TBL] [Abstract][Full Text] [Related]
10. Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs. Morozova N; Avramovič MZ; Markelj G; Toplak N; Avčin T Clin Rheumatol; 2024 Jul; 43(7):2287-2293. PubMed ID: 38775868 [TBL] [Abstract][Full Text] [Related]
11. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study. Tappeiner C; Klotsche J; Sengler C; Niewerth M; Liedmann I; Walscheid K; Lavric M; Foell D; Minden K; Heiligenhaus A Arthritis Rheumatol; 2018 Oct; 70(10):1685-1694. PubMed ID: 29732713 [TBL] [Abstract][Full Text] [Related]
12. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Foell D; Frosch M; Schulze zur Wiesch A; Vogl T; Sorg C; Roth J Ann Rheum Dis; 2004 Feb; 63(2):206-8. PubMed ID: 14722212 [TBL] [Abstract][Full Text] [Related]
13. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis. Bava C; Mongelli F; Pistorio A; Bertamino M; Bracciolini G; Dalprà S; Davì S; Lanni S; Muratore V; Pederzoli S; Rosina S; Schiappapietra B; Suffia C; Varnier G; Verazza S; Giancane G; Consolaro A; Ravelli A Pediatr Rheumatol Online J; 2019 Jul; 17(1):50. PubMed ID: 31345226 [TBL] [Abstract][Full Text] [Related]
14. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic DS; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Johnson A; Huang B; Lovell DJ; J Rheumatol; 2014 Jun; 41(6):1163-70. PubMed ID: 24786928 [TBL] [Abstract][Full Text] [Related]
15. Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration. Fráňová J; Fingerhutová Š; Kobrová K; Srp R; Němcová D; Hoza J; Uher M; Saifridová M; Linková L; Doležalová P Pediatr Rheumatol Online J; 2016 Jun; 14(1):36. PubMed ID: 27301536 [TBL] [Abstract][Full Text] [Related]
16. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial. Alexeeva E; Horneff G; Dvoryakovskaya T; Denisova R; Nikishina I; Zholobova E; Malievskiy V; Santalova G; Stadler E; Balykova L; Spivakovskiy Y; Kriulin I; Alshevskaya A; Moskalev A Pediatr Rheumatol Online J; 2021 Jan; 19(1):5. PubMed ID: 33407590 [TBL] [Abstract][Full Text] [Related]
17. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis. Batu ED; Sönmez HE; Gülhan B; Arıcı ZS; Topaloğlu R; Bilginer Y Turk J Pediatr; 2017; 59(1):6-12. PubMed ID: 29168357 [TBL] [Abstract][Full Text] [Related]
19. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry. Klein A; Becker I; Minden K; Foeldvari I; Haas JP; Horneff G Scand J Rheumatol; 2019 Mar; 48(2):95-104. PubMed ID: 30411654 [TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis. Weiss PF; Xiao R; Brandon TG; Pagnini I; Wright TB; Beukelman T; Morgan-DeWitt E; Feudtner C J Rheumatol; 2018 Jan; 45(1):107-114. PubMed ID: 28916542 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]